|
Perhexiline
drug data and news
Perhexiline drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Perhexiline
|
| Brand Names/Synonyms |
CHEMBANK1158; PERHEXILINE; Perhexilene; Perhexilina [Inn-Spanish]; Perhexiline; Perhexilinum [Inn-Latin]; Perhexilline |
| Indication |
For the management of severe angina pectoris |
|
Sponsored links
|
|
Description |
Not Available |
| Pharmacology |
Used in the treatment of unresponsive or refractory angina. Perhexiline increases glucose metabolism at the expense of free-fatty-acid metabolism, enhancing oxygen efficiency during myocardial ischaemia. Perhexiline also potentiates platelet responsiveness to nitric oxide both in patients with angina and patients with acute coronary syndrome. The predominant mechanism of this particular perhexiline effect is an increase in platelet cGMP responsiveness. Perhexiline also may reduce the potential for nitric oxide clearance by neutrophil-derived oxygen. Perhexiline relieves symptoms of angina, improves exercise tolerance, and increases the workload needed to induce ischaemia when used as monotherapy. The primary therapeutic roles for perhexiline are as short-term therapy (less than 3 months duration) in patients with severe ischaemia awaiting coronary revascularisation or long-term therapy in patients with ischaemic symptoms refractory to other therapeutic measures. |
| Mechanism Of Action |
Perhexiline binds to the mitochondrial enzyme carnitine palmitoyltransferase (CPT)-1 and CPT-2. It acts by shifting myocardial substrate utilisation from long chain fatty acids to carbohydrates through inhibition of CPT-1 and, to a lesser extent, CPT-2, resulting in increased glucose and lactate utilization. |
Perhexiline News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
Not Available |
| Drug_Category |
Vasodilator Agents; Cardiovascular Agents; ATC:C08EX02 |
| Absorption |
Not Available |
| Interactions |
Not Available |
| Toxicity |
Not Available |
| Organisms Affected |
Humans and other mammals |
| Chemical IUPAC Name |
2-(2,2-dicyclohexylethyl)piperidine |
| Chemical Formula |
C19H35N |
| Molecular Weight |
277.488 g/mol |
| Smiles String |
C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3 |
| Melting Point |
Not Available |
| Water Solubility |
Not Available |
| State |
Solid |
| LogP/Hphobicity |
6.054 |
| Isoelectric Point |
Not Available |
| Biotransformation |
Not Available |
| Half Life |
Not Available |
| Protein Binding [%] |
Not Available |
| RxList Link |
Not Available>RXlist |
|
Sponsored links
|
|
| Drug Reference |
Not Available |
| Drug Type |
Approved Drug |
| Accession No |
APRD00107 |
| CAS Registry Number |
6621-47-2 |
| KEGG Compound ID |
Not Available |
| PubChem ID |
SID:165685 |
| PharmGKB ID |
PA130150436 |
| SwissProt ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
Not Available
|
|
|
